My watch list
my.bionity.com  
Login  

133 Current news of Bayer

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Bayer: Good start to 2020

Activities marked by COVID-19

27-Apr-2020

The Bayer Group has registered a good start to 2020, with business activities in the first quarter greatly marked by the COVID-19 pandemic. “With our life science product portfolio in the areas of health and nutrition, we have shown our ability to successfully continue our business operations in ...

more

Bayer strategically and operationally successful

27-Feb-2020

Bayer was strategically and operationally successful last year. “We delivered in 2019 and kept our promises in all areas,” Werner Baumann, Chairman of the Board of Management, said on Thursday at the Financial News Conference in Leverkusen. “We achieved our financial targets despite coming up ...

more

image description
Norbert Winkeljohann to succeed Werner Wenning as Chairman of Bayer’s Supervisory Board

26-Feb-2020

Prof. Dr. Norbert Winkeljohann, 62, is to become Chairman of the Supervisory Board of Bayer AG. As decided at Supervisory Board meeting, Winkeljohann will succeed Werner Wenning, 73, who is to step down with effect from the end of the Annual Stockholders’ Meeting on April 28, 2020. Winkeljohann ...

more

Bayer and Nuvisan create new research unit in Berlin

Bayer to retain significant research activities and headquarters for the company’s Pharmaceuticals Division in Berlin

12-Feb-2020

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in ...

more

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence

10-Jan-2020

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia’s proprietary AI drug discovery platform and drug design know-how ...

more

Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome

Milestone payments potentially more than EUR 330 million

10-Jan-2020

Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies will ...

more

image description
Bayer invests USD 50 Million in eGenesis Series B financing round

Investment to support development of human-compatible xeno organs to address the global organ shortage crisis

11-Nov-2019

eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures ...

more

Bayer: Encouraging business performance across all divisions

Agreements signed to divest Currenta and Animal Health

30-Oct-2019

Bayer has made progress in all key areas and is on track both operationally and strategically. “Bayer had a successful third quarter,” Werner Baumann, Chairman of the Board of Management, said on Wednesday during the news conference call on the quarterly figures. “We increased the Group’s sales ...

more

Bayer reduces size of Board of Management from seven to five members

11-Sep-2019

The Supervisory Board of Bayer AG on Tuesday decided to reduce the size of the company’s Board of Management from seven to five members effective January 1, 2020. Dr. Hartmut Klusik (63) and Kemal Malik (56) will leave the company as of December 31, 2019. As part of the previously communicated ...

more

Bayer acquires BlueRock Therapeutics

09-Aug-2019

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary ...

more

Page 1 From 14
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE